Author

T. Suske

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

R. Moriggl· 3 shared B. Maurer· 2 shared C. Wagner· 2 shared F. Grebien· 2 shared H. A. Neubauer· 2 shared H. Sorger· 2 shared M. Dahlhoff· 2 shared M. Herling· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. Moriggl

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

D. Pölöske, H. Sorger, A. Schönbichler, E. D. de Araujo, H. A. Neubauer, A. Orlova, S. H. Timonen, D. I. Abdallah, A. Ianevski, H. Kuusanmäki, M. Surbek, C. Wagner, T. Suske, M. L. Metzelder, M. Bergmann, , R. Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

bioRxiv · Oct 12, 2023 · PreprintCancer Biology

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

The neonatal microenvironment programs conventional and intestinal Tbet+ γδT17 cells through the transcription factor STAT5

D. Kadekar, R. Agerholm, J. Rizk, H. Neubauer, T. Suske, B. Maurer, M. T. Vinals, E. Comelli, A. Taibi, R. Moriggl, V. Bekiaris

This study shows STAT5 is critical for neonatal expansion of γδT17 cells, which acquire tissue-specific traits necessary for immunity and autoimmunity.

bioRxiv · Jun 3, 2019Immunology